Heat Biologics Gross Profit

Heat Biologics posts a gross profit of $3T as of September 2025. That compares with $830K in the prior-year period — up 361134561.4% year over year. That is above the Healthcare sector average of $67B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Heat Biologics's gross profit was $830K. The latest reading is $3T — a 361134561.4% year-over-year increase (period ending September 2025). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $67B is typical. Heat Biologics's $3T is higher that level. That is roughly 4339.5% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Heat Biologics's financial statement story. At $3T, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for HTBX's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $67B), and (3) consistency with growth and profitability. This page covers the first two; Heat Biologics's other metric pages and overview cover the third.